| Methods |
Multi‐centre RCT |
| Participants |
956 women randomised
All stage 1, differentiation not stated
Progestagen group . < 1/3 myometrial involvement 79 (27.9%), >1/3 myometrial involvement 86 (30.3%)
Control group < 1/3 myometrial involvement 80 (28.5%), > 1/3 myometrial involvement 80 (28.5%) |
| Interventions |
Pre‐operative radiotherapy group: intra‐muscular 500mg Medroxy progesterone acetate once weekly for 14 weeks
Hysterectomy only group: intra‐muscular 1000mg Medroxy progesterone acetate for 14 weeks |
| Outcomes |
Overall death rates |
| Notes |
Completed protocol progestagen group 285
Completed protocol control group 287
No data for intention to treat
Duration of follow‐up; 48 months |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Not reported |
| Allocation concealment (selection bias) |
Unclear risk |
Not reported |
| Blinding (performance bias and detection bias)
All outcomes |
Unclear risk |
Not reported |
| Incomplete outcome data (attrition bias)
All outcomes |
Low risk |
% analysed: 563/574 (98%) |
| Selective reporting (reporting bias) |
Unclear risk |
Insufficient information to permit judgement |
| Other bias |
Unclear risk |
Insufficient information to assess whether an important risk of bias exists |
